C. Badshah

发表

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C‐SCAPE study

A. Zekry, G. Foster, E. Zuckerman, 2018, Journal of viral hepatitis.

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial

Nguyen Dang Quang, N. Gallagher, A. Luxembourg, 2021, Human vaccines & immunotherapeutics.

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic‐Cell Transplantation

Michael Boeckh, Yoshinobu Kanda, Hermann Einsele, 2017, The New England journal of medicine.

The rising concern of community-acquired methicillin-resistant Staphylococcus aureus central nervous system infections: 2 case reports

H. Anyimadu, T. Schliep, V. Sivapalan, 2010 .

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations

H. Teppler, Valerie Teal, J. Mallolas, 2019, Journal of acquired immune deficiency syndromes.

Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial

Valerie Teal, S. Mt-Isa, S. Dadwal, 2021, PharmacoEconomics - Open.

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation

R. Leavitt, Valerie Teal, P. Ljungman, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries

Agust Ingi Agustsson, Maria Hortlund, J. Dillner, 2020, EClinicalMedicine.

Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation

R. Leavitt, Valerie Teal, P. Ljungman, 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Austrian Syndrome (Triad of Pneumococcal Pneumonia, Meningitis and Endocarditis) in an Intravenous Drug User: A Case Report

Naima Zaheer, C. Badshah, R. Nog, 2010 .

The Leader Polypeptide of Theiler's Murine Encephalomyelitis Virus Is Required for the Assembly of Virions in Mouse L Cells

K. Rundell, M. Calenoff, C. Badshah, 2000, Journal of Virology.

The leader polypeptide of Theiler's virus is essential for neurovirulence but not for virus growth in BHK cells

H. Lipton, M. Calenoff, M. D. Dal Canto, 1995, Journal of virology.

P0771 : C-SCAPE: Efficacy and safety of 12 weeks of grazoprevir +/- elbasvir +/- ribavirin in patients with HCV GT2, 4, 5 or 6 infection

A. Howe, A. Zekry, G. Foster, 2015 .

Exposure–Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients

R. Leavitt, K. Dykstra, J. Stone, 2021, Clinical pharmacology and therapy.

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended from 100 to 200 Days Post-Transplant in Cytomegalovirus (CMV)-Seropositive Recipients (R+) of an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

D. Russo, B. Haber, M. Stelljes, 2023, Transplantation and Cellular Therapy.

Physicians Abstracts

G. Sauvageau, S. Landais, P. Zandstra, 2017, Bone Marrow Transplantation.

Community-Acquired Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Brain Abscess: A Case Report and Review of Literature

C. Badshah, R. Nog, 2011 .

2563. Cytomegalovirus (CMV) Prophylaxis with Letermovir (LET) in Pediatric (Birth to < 18 years of age) Allogeneic Hematopoietic Cell Transplant (HCT) Recipients: Pharmacokinetics (PK), Safety and Efficacy Results of a Phase 2b study

C. Badshah, Aharon Gefen, Andreas H. Groll, 2023, Open Forum Infectious Diseases.